New eye drug PMC-403 tested in humans for first time

NCT ID NCT05953012

Completed Disease control Sponsor: PharmAbcine Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a new drug called PMC-403 in 17 people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. The drug is injected directly into the eye. The main goal was to check safety and find the best dose for future studies. The trial is now complete, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PMC-403 (injected into the eye)
What this could lead to: If safe, this could lead to a new treatment option for wet age-related macular degeneration, potentially offering an alternative to current therapies.
What could go wrong: This is a very early Phase 1 trial with only 17 people, focused on safety, not effectiveness. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Contacts and locations

Locations

ASAN Medical Center

Seoul, Songpa-gu, 05505, South Korea
Seoul National University Bundang Hospital

Seoul, Bundang-gu, 13620, South Korea
Yeungnam University

Daegu, Nam-gu, 42415, South Korea
Yonsei University Health System

Seoul, Seodaemun-gu, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.